The use of antithrombotic drugs in older people

Minerva Medica

Volumn 93, Issue 1, 2002, Pages 13-26

  Tufano, A ^a   Cerbone, A M ^a   Di Minno, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Administration and dosage; Aged; Fibrinolytic agents; Fibrinolytic agents, therapeutic use; Myocardial infarction, therapy; Venous thrombosis, therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; STREPTOKINASE; TICLOPIDINE; TINZAPARIN; WARFARIN;

AGED; AGING; ANGINA PECTORIS; ARTERY DISEASE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; THROMBOEMBOLISM;

AGED; ASPIRIN; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PULMONARY EMBOLISM; RECURRENCE; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; TICLOPIDINE; VENOUS THROMBOSIS; WARFARIN;

EID: 0036217369     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update
2. Thrombolytic therapy for elderly patients
3. Population-based distributions of haemostatic variables
4. Hypercoagulability in centenarians: The paradox of successful aging
5. The epidemiology of diagnosed pulmunary embolism and deep vein thrombosis in the elderly
6. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
7. Drugs that have influenced our practice in the treatment of venous thromboembolism
8. Treatment options for acute venous thromboembolism in the older patient
9. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
10. Collaborative overview of randomized trials of antiplatelet therapy. II: Manteinance of vascular graft or arterial patency by antiplatelet therapy
11. Collaborative overview of randomized trials of antiplatelet therapy. III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
12. Arachidonate metabolism in vascular disorders
13. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2
14. Aspirin in the treatment of acute myocardial infarction in elderly medicare beneficiaries. Patterns of use and outcomes
15. Swedish Aspirin Lowdose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events
16. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomised trial
17. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
18. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
19. Platelet-active drugs. The relationships among dose, effectiveness, and side effects
20. The Canadian-American Ticlopidine Study (CATS) in the thromboembolic stroke
21. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients
22. Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial
23. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine: Results from STIMS, the Swedish Ticlopidine Multicenter Study
24. Prevention of aortocoronary bypass graft occlusion: Beneficial effect of ticlopidine on early and late patency rate of venous coronary bypass grafts: A double-blind study
25. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
26. Randomised trial of prophylactic daily aspirin in British male doctors
27. Final report on the aspirin component of the ongoing Physicians' Health Study
28. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
29. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
30. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomized trial in general practice
31. ACC/AHA Guidelines for the management of patients with acute myocardial infarction: Executive summary
32. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
33. Low-molecular-weight heparin during instability in coronary artery disease
34. Comparison of low-molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
35. A comparison of low-molecularweight heparin with unfractionated heparin for unstable coronary artery disease
36. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non Q-wave myocardial infarction
37. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
38. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
39. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI IIb-ESSENCE meta-analysis
40. Thrombolysis in acute myocardial infarction
41. Coronary thrombolysis for the erderly?
42. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
43. Randomised controlled trial of subcutaneous calcium heparin in acute myocardial infarction
44. An International randomized trial comparing four thrombolytic strategies for acute myocardial infarction
45. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized clinical trials of more than 1,000 patients
46. Management of heparin therapy. Controlled prospective trial
47. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time
48. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis
49. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: A randomised trial
50. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis
51. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
52. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism
53. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
54. Complications of anticoagulation for pulmonary embolism in low risk trauma patients
55. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis
56. A deep-vein thrombosis treated with streptokinase or heparin: Follow-up of a randomized study
57. Rapid thrombolysis and preservation of valvular venous function in higl deep veinthrombosis
58. Comparison of streptokinase with heparin: Late results in the treatment of deep vein thrombosis
59. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in acute pulmonary embolism
60. Antithrombotic therapy for venous thromboembolic disease
61. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism
62. Urokinase-Streptokinase embolism trial: Phase 2 results a cooperative study
63. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis
64. Safety of thrombolitic therapy in elderly patients with massive pulmonary embolism: A comparison with non-elderly patients
65. Treatment of deep venous thrombosis with low-molecularweight heparins
66. Low molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
67. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for deep-vein thrombosis
68. Treatment of venous thromboembolism with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
69. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
70. Guidelines on oral anticoagulation: Third edition
71. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindication to coumarin
72. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
73. Efficacy of low-doses of heparin in prevention of deep-vein thrombosis after major surgery: A double-blind randomized trial
74. Failure of low-dose heparin to prevent deep vein thrombosis after hip replacement arthroplasty
75. Prevention of deep vein thrombosis in urological patients: A controlled randomized trial of low-dose heparin and external pneumatic compression boots
76. Adjusted versus fixed dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement
77. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xa I units in 2070 patients
78. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery
79. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
80. A randomized controlled trial of a lowmolecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
81. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery
82. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
83. Prolonged thromboprophylaxis following hip replacement surgery. Results of a doubleblind prospective, randomised placebo-controlled study with dalteparin (Fragmin)
84. Efficacy and safety of prolonged thromboprophylaxis with a low-molecular weight heparin (dalteparin) after total hip artroplasty. The Danish prolonged prophylaxis (DaPP) Study
85. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
86. Antithrombotic therapy in atrial fibrillation
87. Thromboprophilaxis, for atrial fibrillation
88. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study
89. SPAF Study. Final Results
90. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study
91. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
92. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology
93. Secondary prevention in nonrheumatic atrial fibrillation after a transient ischemic attack or minor stroke
94. Bleeding complication of oral anticoagulant treatment: An inception-cohort, Prospective Italian Study (ISCOAT)
95. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
96. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
97. The second copenhagen atrial fibrillation, aspirin and anticoagulant therapy. (AFASAK II) methods and design
98. Adjusted-dose warfarin versus low-intensity, fixeddose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial
99. Antithrombotic therapy in atrial fibrillation